Allspring Global Investments Holdings LLC Acquires 2,030 Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR)

Allspring Global Investments Holdings LLC grew its holdings in Voyager Therapeutics, Inc. (NASDAQ:VYGRFree Report) by 2.1% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 99,306 shares of the company’s stock after buying an additional 2,030 shares during the period. Allspring Global Investments Holdings LLC owned approximately 0.18% of Voyager Therapeutics worth $925,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in VYGR. Gladius Capital Management LP purchased a new position in Voyager Therapeutics in the third quarter worth about $25,000. AJOVista LLC bought a new stake in shares of Voyager Therapeutics in the 4th quarter valued at approximately $39,000. China Universal Asset Management Co. Ltd. purchased a new position in shares of Voyager Therapeutics in the 4th quarter worth approximately $43,000. Tower Research Capital LLC TRC increased its position in shares of Voyager Therapeutics by 302.5% during the 4th quarter. Tower Research Capital LLC TRC now owns 6,399 shares of the company’s stock valued at $54,000 after purchasing an additional 4,809 shares during the last quarter. Finally, Ritholtz Wealth Management raised its holdings in Voyager Therapeutics by 11.8% during the 4th quarter. Ritholtz Wealth Management now owns 19,759 shares of the company’s stock valued at $167,000 after buying an additional 2,089 shares during the period. 48.03% of the stock is currently owned by institutional investors.

Voyager Therapeutics Stock Performance

Voyager Therapeutics stock opened at $7.79 on Tuesday. The company has a market capitalization of $423.70 million, a PE ratio of -155.77 and a beta of 0.96. The company has a 50 day moving average price of $8.27 and a 200-day moving average price of $8.38. Voyager Therapeutics, Inc. has a fifty-two week low of $6.06 and a fifty-two week high of $11.72.

Voyager Therapeutics (NASDAQ:VYGRGet Free Report) last released its quarterly earnings data on Monday, May 13th. The company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.24. Voyager Therapeutics had a negative return on equity of 1.28% and a negative net margin of 2.56%. The company had revenue of $19.52 million for the quarter, compared to the consensus estimate of $10.33 million. On average, analysts forecast that Voyager Therapeutics, Inc. will post -1.39 earnings per share for the current year.

Analyst Ratings Changes

VYGR has been the subject of several recent analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price objective on shares of Voyager Therapeutics in a research note on Thursday, May 16th. StockNews.com cut shares of Voyager Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, May 13th. Guggenheim assumed coverage on shares of Voyager Therapeutics in a research note on Tuesday, March 26th. They issued a “buy” rating and a $22.00 price objective for the company. Wedbush cut their target price on Voyager Therapeutics from $10.00 to $8.00 and set a “neutral” rating on the stock in a research note on Tuesday, May 14th. Finally, Oppenheimer reissued an “outperform” rating and set a $18.00 price target on shares of Voyager Therapeutics in a research note on Wednesday, May 15th. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $18.00.

Read Our Latest Report on VYGR

Voyager Therapeutics Company Profile

(Free Report)

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.

Featured Articles

Want to see what other hedge funds are holding VYGR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Voyager Therapeutics, Inc. (NASDAQ:VYGRFree Report).

Institutional Ownership by Quarter for Voyager Therapeutics (NASDAQ:VYGR)

Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.